Back to top
more

Thermo Fisher Scientific (TMO)

(Delayed Data from NYSE)

$618.46 USD

618.46
1,323,173

-5.75 (-0.92%)

Updated Sep 11, 2024 04:00 PM ET

After-Market: $618.47 +0.01 (0.00%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Varian (VAR) Earnings and Revenues Surpass Estimates in Q3

Varian's (VAR) Proton Solutions unit saw revenue growth in Q3.

ABIOMED (ABMD) Earnings and Revenues Beat Estimates in Q1

ABIOMED's (ABMD) flagship Impella saw decline in revenues internationally and within the United States, in Q1.

LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss

LHC Group's (LHCG) second-quarter results benefit from strength in hospice services.

Cardinal Health (CAH) Q4 Earnings Top Estimates, Revenues Lag

Cardinal Health's (CAH) fiscal fourth-quarter results reflect weak segmental performance.

Becton Dickinson (BDX) Earnings Surpass Estimates in Q3

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in Q3.

DENTSPLY SIRONA (XRAY) Q2 Earnings & Revenues Miss Estimates

DENTSPLY SIRONA's (XRAY) second-quarter 2020 results reflect weak segmental performance.

CVS Health (CVS) Q2 Earnings Top Estimates, 2020 View Up

CVS Health's (CVS) Health Care Benefits segment registers membership growth in Q2.

Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates

Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Down

Haemonetics' (HAE) first-quarter fiscal 2021 results reflect impressive performance by Blood Center segment despite dismal overall performance during the coronavirus-led crisis.

Fresenius Medical (FMS) Q2 Earnings & Revenues Top Estimates

Fresenius Medical's (FMS) second-quarter earnings benefit from strong segmental performance.

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

AmerisourceBergen's (ABC) fiscal third-quarter earnings benefit from segmental growth.

Patterson Cos. (PDCO) Hits 52-Week High, Can the Run Continue?

Patterson Cos. (PDCO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Luminex (LMNX) Q2 Earnings Beat Estimates, Revenues Miss

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in Q2

Inogen's (INGN) Q2 Earnings Beat Estimates, Revenues Miss

Inogen (INGN) saw growth in revenues within its Rental segment in Q2.

QIAGEN (QGEN) Q2 Earnings In Line With Estimates, Margins Up

QIAGEN (QGEN) registered robust revenue growth across majority of geographies and both operating segments in Q2 despite the coronavirus-led economic crisis.

Zimmer Biomet's (ZBH) Q2 Earnings Beat, Margins Contract

Zimmer Biomet's (ZBH) second-quarter elective procedure volumes decline across all regions.

Urmimala Biswas headshot

3 Medical Product Stocks Set to Beat This Earnings Season

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Bruker (BRKR) Q2 Earnings Surpass Estimates, Margins Fall

Bruker's (BRKR) second-quarter 2020 results reflect dismal performance by all segments and geographies due to coronavirus-led business disruptions.

Henry Schein (HSIC) Q2 Earnings Top Estimates, Margins Dip

Henry Schein (HSIC) sees dismal segmental performance in Q2 due to disruptions resulting from the coronavirus pandemic.

STERIS' (STE) Earnings & Revenues Surpass Estimates in Q1

STERIS' (STE) first-quarter fiscal 2021 results reflect strong performance by the Life Sciences segment despite the coronavirus-led economic crisis.

Pacific Biosciences (PACB) Posts Lower-Than-Expected Q2 Loss

Pacific Biosciences (PACB) saw revenue decline in both its operating segments in Q2.

LabCorp (LH) Banks on Covance Amid Testing Volume Pressure

LabCorp's (LH) COVID-19 related research too has been progressing well.

McKesson (MCK) Q1 Earnings and Revenues Surpass Estimates

McKesson's (MCK) fiscal first-quarter 2021 results benefit from strong U.S. Pharmaceutical and Specialty Solutions segment.

Hill-Rom's (HRC) Q3 Earnings Top Estimates, Margins Expand

Hill-Rom (HRC) benefits from increased demand for critical care products due to the coronavirus outbreak.

Allscripts (MDRX) Q2 Earnings and Revenues Beat Estimates

Allscripts (MDRX) witnessed decline in core Client Services and Software delivery unit revenues during Q2.